PRESS RELEASE
THE DARK REPORT
21806 Briarcliff Dr.
Spicewood, Texas 78669
512-264-7103 o
512-264-0969 f
FOR IMMEDIATE RELEASE
Media Contact: Chris Garcia
chris@darkreport.com
AUSTIN, Texas (August 1, 2016) – Increased understanding of the genetic basis of an individual’s response to drugs, including how and how quickly a drug is metabolized (pharmacodynamics and pharmacokinetics), has opened the door to a more personalized approach to drug prescription. By identifying drugs most likely to benefit a patient, assessing the likely dose response, potentially avoiding adverse reactions, and reducing unnecessary use of drugs, pharmacogenomics testing (PgX) is helping to optimize treatment and reduce costs associated with complications or inappropriate utilization.
“As research demonstrating the clinical utility and associated health economics benefits of PgX grows—along with the increasing trends toward value-based healthcare—PgX is on the path to becoming the standard of care,” states Robert L. Michel, Editor-In-Chief of The Dark Report. “This demand for PgX presents a tremendous opportunity for clinical laboratories, many of which have already over the last few years successfully launched PgX services, and enjoyed robust growth.”
Indispensable insights and key observations gleaned from an expert panel of lab directors and consultants regarding the status of PgX today, as well as its future outlook, comprise a recently published white paper from The Dark Report, entitled “A Lab Leader’s Guide To Pharmacogenomic Testing (PGx).” Published by The Dark Report and Dark Daily, it is available free to laboratory professionals as a PDF download.
This white paper provides clinical lab managers the latest information on industry trends, best practices and guidance for labs looking to tap into the latest, most relevant, and potentially successful PgX opportunities, and includes discussion regarding:
- Why the long-term outlook for PgX is still favorable, even given recent setbacks
- Clinical specialties most likely to order PgX and how labs can forge successful relationships with these physicians
- Benchmarks for providing top-quality PgX results to physician clients
- Workflow parameters for a lab to consider as it looks toward expanding its PgX testing capabilities and improving relevant throughput
- How to reduce unknowns regarding the demonstration of medical necessity and address reimbursement risk
- Actionable tips for those laboratories just getting started with a PgX practice
- What lies ahead for PgX and key recommendations for preparing the laboratory
Ongoing discoveries and advancing technologies are creating rich opportunities for the establishment and expansion of PgX services, and will continue to do so. Expertise such as this that is beyond traditional lab medicine is crucial to the future success of all laboratories, which means that it is essential that the laboratory manager or executive learn more about the growing opportunities associated with PgX services. This White Paper provides essential information to guide the laboratory professional regarding the key elements of a PgX practice.
To download “A Lab Leader’s Guide To Pharmacogenomic Testing (PGx),” click here. This is a free publication and part of the Dark Daily Resource Center, comprised of a growing library of white papers and other information resources tailored specifically to the needs of laboratory administrators, lab managers, pathologists, and lab industry consultants.
For additional information, Contact: Chris Garcia, 512-264-7103
About THE DARK REPORT
Established in 1995, THE DARK REPORT is the leading source of exclusive business intelligence for laboratory CEOs, COOs, CFOs, Pathologists and Senior industry executives. It is widely read by leaders in laboratory medicine and diagnostics. The Dark Report produces the famous Executive War College on Laboratory and Pathology Management every spring, which showcases innovations by the nation’s and globe’s leading laboratory organizations. Dark Daily is an Internet-based e-briefing intelligence service, read worldwide by thought leaders in laboratory and pathology management. Other well-known conferences conducted by THE DARK REPORT are Lab Quality Confab (on the use of Lean and Six Sigma methods in labs and hospitals) and Molecular Summit (on the integration of in vivo and in vitro diagnostics). THE DARK REPORT co-produces Frontiers in Laboratory Medicine annually in the United Kingdom; Executive Edge bi-annually in Canada; and The Business of Pathology bi-annually in Australia.
-end-
